Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

finerenone

- PMLiVE

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

CKD is a progressive condition that affects nearly 850 million people worldwide

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in long-term study

Vasomotor symptoms are reported by up to 80% of women during the menopausal transition

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

Bayer symbol

Bayer and BridgeBio enter European partnership worth up to $310m for ATTR-CM

The rare and progressive condition affects around 500,000 people worldwide

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in phase 3 studies

Vasomotor symptoms are estimated to affect up to 80% of menopausal women

- PMLiVE

Novo Nordisk to buy KBP’s hypertension drug ocedurenone for up to $1.3bn

An estimated 1.28 billion adults aged 30 to 79 years worldwide have hypertension

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

Vironix and Oxford University partner to advance chronic kidney disease monitoring

The partners will aim to develop learning models that predict the progression of CKD

- PMLiVE

Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease

Approximately 47 million people in the EU are affected by the long-term kidney condition

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

Bayer symbol

Bayer and BlueRock announce positive early-stage results for Parkinson’s cell therapy

The progressive neurological disorder affects around ten million people worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links